Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 38

1.

Identification of a candidate gene panel for the early diagnosis of prostate cancer.

Leyten GH Giseleleyten Hotmail Com, Hessels D, Smit F, Jannink S, de Jong H, Melchers WJ, Cornel EB, de Reijke TM, Vergunst H, Kil P, Knipscheer BC, Hulsbergen-van de Kaa CA, Mulders PF, van Oort IM, Schalken JA.

Clin Cancer Res. 2015 Mar 18. pii: clincanres.3334.2014. [Epub ahead of print]

PMID:
25788493
2.

Results of a phase 1 dose escalation study of intravesical TMX-101 in patients with nonmuscle invasive bladder cancer.

Falke J, Lammers RJ, Arentsen HC, Ravic M, Pozzi R, Cornel EB, Vergunst H, de Reijke TM, Witjes JA.

J Urol. 2013 Jun;189(6):2077-82. doi: 10.1016/j.juro.2012.11.150. Epub 2012 Nov 30.

PMID:
23206424
3.

Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer.

Leyten GH, Hessels D, Jannink SA, Smit FP, de Jong H, Cornel EB, de Reijke TM, Vergunst H, Kil P, Knipscheer BC, van Oort IM, Mulders PF, Hulsbergen-van de Kaa CA, Schalken JA.

Eur Urol. 2014 Mar;65(3):534-42. doi: 10.1016/j.eururo.2012.11.014. Epub 2012 Nov 15.

PMID:
23201468
4.

Active surveillance for low-risk prostate cancer worldwide: the PRIAS study.

Bul M, Zhu X, Valdagni R, Pickles T, Kakehi Y, Rannikko A, Bjartell A, van der Schoot DK, Cornel EB, Conti GN, Boevé ER, Staerman F, Vis-Maters JJ, Vergunst H, Jaspars JJ, Strölin P, van Muilekom E, Schröder FH, Bangma CH, Roobol MJ.

Eur Urol. 2013 Apr;63(4):597-603. doi: 10.1016/j.eururo.2012.11.005. Epub 2012 Nov 12.

PMID:
23159452
5.

Re: Vincenzo Pagliarulo, Sergio Bracarda, Mario A. Eisenberger, et al. Contemporary role of androgen deprivation therapy for prostate cancer. Eur Urol 2012;61:11–25.

Cornel EB.

Eur Urol. 2012 Jun;61(6):e59; author reply e60. doi: 10.1016/j.eururo.2012.02.048. Epub 2012 Feb 25. No abstract available.

PMID:
22386192
6.

Phase 2 study of adjuvant intravesical instillations of apaziquone for high risk nonmuscle invasive bladder cancer.

Hendricksen K, Cornel EB, de Reijke TM, Arentsen HC, Chawla S, Witjes JA.

J Urol. 2012 Apr;187(4):1195-9. doi: 10.1016/j.juro.2011.11.101. Epub 2012 Feb 14.

PMID:
22335860
7.
8.

Transurethral resection of bladder tumours.

Cornel EB.

BJU Int. 2010 Oct;106(8):1237. doi: 10.1111/j.1464-410X.2010.09778.x. No abstract available.

PMID:
21156035
9.

Re: Fritz H. Schröder, Monique J. Roobol. The REDUCE Trial. Eur Urol 2010;58:253-255.

Cornel EB.

Eur Urol. 2011 Jan;59(1):e1. doi: 10.1016/j.eururo.2010.09.037. Epub 2010 Oct 8. No abstract available.

PMID:
20951493
10.

The 1-year outcome of the transobturator retroluminal repositioning sling in the treatment of male stress urinary incontinence.

Elzevier HW, Cornel EB.

BJU Int. 2010 Oct;106(7):1091; author reply 1091-2. doi: 10.1111/j.1464-410X.2010.09721_1.x. No abstract available.

PMID:
20840320
11.

Effect of dutasteride on the risk of prostate cancer.

Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson TH, Fowler IL, Rittmaster RS; REDUCE Study Group.

N Engl J Med. 2010 Apr 1;362(13):1192-202. doi: 10.1056/NEJMoa0908127.

12.

Can advance transobturator sling suspension cure male urinary postoperative stress incontinence?

Cornel EB, Elzevier HW, Putter H.

J Urol. 2010 Apr;183(4):1459-63. doi: 10.1016/j.juro.2009.12.013. Epub 2010 Feb 20.

PMID:
20172561
13.

Short-term outcomes of the prospective multicentre 'Prostate Cancer Research International: Active Surveillance' study.

van den Bergh RC, Vasarainen H, van der Poel HG, Vis-Maters JJ, Rietbergen JB, Pickles T, Cornel EB, Valdagni R, Jaspars JJ, van der Hoeven J, Staerman F, Oomens EH, Rannikko A, Roemeling S, Steyerberg EW, Roobol MJ, Schröder FH, Bangma CH.

BJU Int. 2010 Apr;105(7):956-62. doi: 10.1111/j.1464-410X.2009.08887.x. Epub 2009 Oct 8.

PMID:
19817747
14.

Two-year follow-up of the phase II marker lesion study of intravesical apaziquone for patients with non-muscle invasive bladder cancer.

Hendricksen K, van der Heijden AG, Cornel EB, Vergunst H, de Reijke TM, van Boven E, Smits GA, Puri R, Gruijs S, Witjes JA.

World J Urol. 2009 Jun;27(3):337-42. doi: 10.1007/s00345-009-0382-4. Epub 2009 Feb 13.

15.

Allelic imbalance analysis using a single-nucleotide polymorphism microarray for the detection of bladder cancer recurrence.

Coenen MJ, Ploeg M, Schijvenaars MM, Cornel EB, Karthaus HF, Scheffer H, Witjes JA, Franke B, Kiemeney LA.

Clin Cancer Res. 2008 Dec 15;14(24):8198-204. doi: 10.1158/1078-0432.CCR-08-1103.

16.

Sequence variant on 8q24 confers susceptibility to urinary bladder cancer.

Kiemeney LA, Thorlacius S, Sulem P, Geller F, Aben KK, Stacey SN, Gudmundsson J, Jakobsdottir M, Bergthorsson JT, Sigurdsson A, Blondal T, Witjes JA, Vermeulen SH, Hulsbergen-van de Kaa CA, Swinkels DW, Ploeg M, Cornel EB, Vergunst H, Thorgeirsson TE, Gudbjartsson D, Gudjonsson SA, Thorleifsson G, Kristinsson KT, Mouy M, Snorradottir S, Placidi D, Campagna M, Arici C, Koppova K, Gurzau E, Rudnai P, Kellen E, Polidoro S, Guarrera S, Sacerdote C, Sanchez M, Saez B, Valdivia G, Ryk C, de Verdier P, Lindblom A, Golka K, Bishop DT, Knowles MA, Nikulasson S, Petursdottir V, Jonsson E, Geirsson G, Kristjansson B, Mayordomo JI, Steineck G, Porru S, Buntinx F, Zeegers MP, Fletcher T, Kumar R, Matullo G, Vineis P, Kiltie AE, Gulcher JR, Thorsteinsdottir U, Kong A, Rafnar T, Stefansson K.

Nat Genet. 2008 Nov;40(11):1307-12. doi: 10.1038/ng.229. Epub 2008 Sep 14.

PMID:
18794855
17.

The effect on pain experienced by male patients of watching their office-based flexible cystoscopy.

Cornel EB, Oosterwijk E, Kiemeney LA.

BJU Int. 2008 Nov;102(10):1445-6. doi: 10.1111/j.1464-410X.2008.07777.x. Epub 2008 Jun 6.

PMID:
18540935
18.

Benign prostatic hyperplasia as a progressive disease: a guide to the risk factors and options for medical management.

Emberton M, Cornel EB, Bassi PF, Fourcade RO, Gómez JM, Castro R.

Int J Clin Pract. 2008 Jul;62(7):1076-86. doi: 10.1111/j.1742-1241.2008.01785.x. Epub 2008 May 8. Review.

19.

Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer.

Hessels D, Smit FP, Verhaegh GW, Witjes JA, Cornel EB, Schalken JA.

Clin Cancer Res. 2007 Sep 1;13(17):5103-8.

20.

Molecular PCA3 diagnostics on prostatic fluid.

van Gils MP, Cornel EB, Hessels D, Peelen WP, Witjes JA, Mulders PF, Rittenhouse HG, Schalken JA.

Prostate. 2007 Jun 1;67(8):881-7.

PMID:
17440939
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk